From Wikipedia, the free encyclopedia
"Delcath" redirects here. For other uses, see Delcath (disambiguation).
Delcath Systems, Inc. is a developer of percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in New York, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion.
[edit] References
[edit] External links
- Delcath official website
- ClinicalTrials.gov NCT00324727 - metastatic melanoma in the liver
- ClinicalTrials.gov NCT00096083 - primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas
- Pingpank, James F. Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemfiltration Using Percutaneously Placed Catheters in Patients with Unresectable Hepatic Malignancies. J Clin Oncol 23:3456-3474.
- Seidel, Geoffrey D. Part I: Regional Chemotherapy Clinical Studies in Nontraditional Clinical Settings. 10.1188/06.CJON.338-344.
- Allbusiness.com
